Newsroom

Walden Biosciences Fully Enrolls First Cohort in Phase 2 Basket Study of WAL0921 in Chronic Kidney Diseases

October 2, 2024

Walden Biosciences Announces Research Collaboration with World Renowned Genetic Epidemiologist to Advance Work on Causal Role of suPAR in Chronic Kidney Disease

May 13, 2024

Walden Biosciences Announces Positive Topline Data from Phase 1+ Clinical Study of WAL0921 in Development for Treatment of Kidney Diseases

April 15, 2024

Walden Biosciences Expands Research Collaboration with the University of Michigan

January 10, 2024

Walden Biosciences to Host Virtual Event on November 14, 2023 “Transforming the Treatment Landscape of Chronic Kidney Disease”

November 7, 2023

Walden Biosciences Announces First Subject Dosed in First-in-Humans Phase 1 Clinical Trial of WAL0921, in Development for Treatment of Chronic Kidney Diseases

June 5, 2023

12 3 4